Article Sidebar
Published:
Oct 8, 2024Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effect of anti-osteoporotic drugs in reducing risk of refracture after percutaneous vertebroplasty
Abstract
Purpose: To investigate the effectiveness of anti-osteoporotic drugs in lowering risk of refracture after percutaneous vertebroplasty. Methods: The study involved 80 patients who underwent percutaneous vertebroplasty in The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China between August 2020 and July 2022. The study group (n = 40) received postoperative rehabilitation in addition to anti-osteoporotic drugs for 6 months), while the control group (n = 40) received routine postoperative rehabilitation from the time of surgery completion to 3 months postoperative. Visual Analogue Scale (VAS) and Oswestry Disability Index (ODI) scores were compared before surgery, 3 days, 3 months, and 6 months postoperative. Changes in the middle height of the vertebral body and bone density T-score of the surgical and adjacent vertebrae before and at end of follow-up, and refracture rates were compared.
Results: The study group showed significantly lower VAS and ODI scores at 3 and 6 months after surgery compared to control group (p < 0.05). Both groups showed significant increase in vertebral body height before surgery (p < 0.05), with no significant difference at last follow-up (p > 0.05). Also, the study group showed significant increase in bone density in the surgical and adjacent vertebrae compared to control group at last follow-up (p < 0.05). Refracture rate was significantly lower in study group than in the control group (p < 0.05). Conclusion: Administering anti-osteoporotic drugs after percutaneous vertebroplasty significantly alleviates pain, improves vertebral bone density, and reduces risk of refracture. However, a largesample, multicenter, randomized prospective study to validate these findings is recommended.
